acetylated peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
The two substrates of this enzyme are L-lysine and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are (2S)-2,3,4,5-tetrahydropyridine-2-carboxylic acid (1), ammonia, reduced NADH, and a proton. The enzyme is highly specific for L-lysine as substrate, although S-(2-aminoethyl)-L-cysteine can act as a substrate, but more slowly.
Nuclear magnetic resonance (NMR) is a physical phenomenon in which nuclei in a strong constant magnetic field are disturbed by a weak oscillating magnetic field (in the near field) and respond by producing an electromagnetic signal with a frequency characteristic of the magnetic field at the nucleus. This process occurs near resonance, when the oscillation frequency matches the intrinsic frequency of the nuclei, which depends on the strength of the static magnetic field, the chemical environment, and the magnetic properties of the isotope involved; in practical applications with static magnetic fields up to ca. 20 tesla, the frequency is similar to VHF and UHF television broadcasts (60–1000 MHz). NMR results from specific magnetic properties of certain atomic nuclei. High-resolution nuclear magnetic resonance spectroscopy is widely used to determine the structure of organic molecules in solution and study molecular physics and crystals as well as non-crystalline materials. NMR is also routinely used in advanced medical imaging techniques, such as in magnetic resonance imaging (MRI). The original application of NMR to condensed matter physics is nowadays mostly devoted to strongly correlated electron systems. It reveals large many-body couplings by fast broadband detection and should not be confused with solid state NMR, which aims at removing the effect of the same couplings by Magic Angle Spinning techniques.
A metabolic network is the complete set of metabolic and physical processes that determine the physiological and biochemical properties of a cell. As such, these networks comprise the chemical reactions of metabolism, the metabolic pathways, as well as the regulatory interactions that guide these reactions. With the sequencing of complete genomes, it is now possible to reconstruct the network of biochemical reactions in many organisms, from bacteria to human. Several of these networks are available online: Kyoto Encyclopedia of Genes and Genomes (KEGG), EcoCyc, BioCyc and metaTIGER. Metabolic networks are powerful tools for studying and modelling metabolism.
The bank did hedge against interest rate risk on its available-for-sale portfolio by building up a portfolio of $15.2 billion of interest rate swaps by the end of 2021. At the same time, startup companies withdrew deposits from the bank to fund their operations as private financing became harder to come by. A series of layoffs in the technology sector that began in 2022 also caused depositors to draw down their savings. During the first half of 2022, the bank realized $517 million in gains by unwinding $11 billion of its interest rate swaps on its available-for-sale bond portfolio. By the end of the year, it had only $563 million in swaps protecting that portfolio. In early 2023, to raise needed cash to fund withdrawals, the bank sold all of its available-for-sale securities, realizing a $1.8 billion loss. The bank was criticized for timing its announcement shortly after Silvergate Bank, which catered to cryptocurrency users, started winding down its operations, and for not lining up private funding ahead of the announcement. Some banking experts said that the bank would have managed its risks better had it not been for the Economic Growth, Regulatory Relief, and Consumer Protection Act (EGRRCPA), enacted in 2018 and supported by SVB CEO Greg Becker, which reduced the frequency and number of scenarios of required stress testing implemented under the Dodd–Frank Wall Street Reform and Consumer Protection Act for banks with under $250 billion in assets. The Federal Reserve Bank of San Francisco did have discretion to annually examine any bank with $100 billion in assets.
=== Swallowing === Food is ingested through the mouth and when swallowed passes first into the pharynx and then into the esophagus. The esophagus is thus one of the first components of the digestive system and the gastrointestinal tract. After food passes through the esophagus, it enters the stomach. When food is being swallowed, the epiglottis moves backward to cover the larynx, preventing food from entering the trachea. At the same time, the upper esophageal sphincter relaxes, allowing a food bolus to enter. Peristaltic contractions of the esophageal muscle push the food down the esophagus. These rhythmic contractions occur both as a reflex response to food that is in the mouth, and also as a response to the sensation of food within the esophagus itself. Along with peristalsis, the lower esophageal sphincter relaxes.
Sources: en.wikipedia.org
A modified variant of the atractylenolide carries an additional carboxyl group at the C4 atom of the atractyligenin, which is then referred to as carboxy-atractyloside (CATR), sometimes referred to as "gummiferin". The ATR/CATR chemical structure on the right indicates this difference between compounds.
== Etymology == The term "Palaeolithic" was coined by archaeologist John Lubbock in 1865. It derives from Greek: παλαιός, palaios, "old"; and λίθος, lithos, "stone", meaning "old age of the stone" or "Old Stone Age".
=== Post B.P.C. Mining === In March 1981, the Phosphate Mining Company of Christmas Island (PMCI), a company established and controlled by the Australian Government, took over mining operations This arrangement lasted until December 1987 when the company was disbanded. The mining operation was then taken over by the Union of Christmas Island Workers.
=== Formulation and delivery === Delivery systems are primarily divided into polymer-based delivery systems (microspheres and liposomes) and live delivery systems (gram-positive bacteria, gram-negative bacteria and viruses)
Sources: en.wikipedia.org
Narrated by Juliet Stevenson (later to narrate many Horizon documentaries), directed by John Simmons, produced by Martine Benoit, made by Geofilms 27 September How They Built the Channel Tunnel, looking at the construction of the two crossover places of the tunnel, as big as two football fields, forty metres below the sea bed; AR Dykes, the President of the British Institution of Structural Engineers in 1976; Gordon Crighton, engineering director of TML, David Wallis, project manager of UK Tunnels of TML; the French end of the tunnel was at Beussingue; it took five years; Colin Kirkland, technical director of Eurotunnel; Richard Lewis of Markhams, a steel fabricator in Chesterfield; geologist Malcolm Bolton of the University of Cambridge; Douglas Parkes of Ove Arup; Stewart Campbell of the HSE; tunnelling began from Folkestone in October 1987; many tunnellers were from North East England and the Irish, such as Jim Ahern; 2,000 tonnes of chalk per hour came out of the tunnel during 1989; the laser guidance was made by Zed Systems of London; 440 metres of tunnel per week could be built; tunnel concrete segments were cast on the Isle of Grain, in Kent; nine workers died in accidents - seven on the English side; there are two cross-over caverns; the English cavern was built from the service tunnel, before the main tunnels arrived; the caverns are 21 metres wide, 16 metres high and 147 metres long, with two movable walls; the British Tunnelling Society; Alan Myers, construction manager of the crossover for UK Tunnels; civil engineer John King.
== Cis–trans isomerization == Peptide bonds to proline, and to other N-substituted amino acids (such as sarcosine), are able to populate both the cis and trans isomers. Most peptide bonds overwhelmingly adopt the trans isomer (typically 99.9% under unstrained conditions), chiefly because the amide hydrogen (trans isomer) offers less steric repulsion to the preceding Cα atom than does the following Cα atom (cis isomer). By contrast, the cis and trans isomers of the X-Pro peptide bond (where X represents any amino acid) both experience steric clashes with the neighboring substitution and have a much lower energy difference. Hence, the fraction of X-Pro peptide bonds in the cis isomer under unstrained conditions is significantly elevated, with cis fractions typically in the range of 3-10%. However, these values depend on the preceding amino acid, with Gly and aromatic residues yielding increased fractions of the cis isomer. Cis fractions up to 40% have been identified for aromatic–proline peptide bonds. From a kinetic standpoint, cis–trans proline isomerization is a very slow process that can impede the progress of protein folding by trapping one or more proline residues crucial for folding in the non-native isomer, especially when the native protein requires the cis isomer. This is because proline residues are exclusively synthesized in the ribosome as the trans isomer form. All organisms possess prolyl isomerase enzymes to catalyze this isomerization, and some bacteria have specialized prolyl isomerases associated with the ribosome.
Formation of excessive scar tissue is thus prevented. The combination of silicone gel sheeting and compression therapy has been proven to be more effective than using the sheet alone. Patients who find the non-invasive treatments ineffective may choose to undergo invasive treatments such as intralesional injections of corticosteroids, surgical excision of the scars, and radiotherapy.
The traditional kava beverage is prepared through aqueous extraction of the fresh or dried roots of the Piper methysticum plant. When using fresh roots, the outer layer is typically peeled before the root is either chewed or mechanically ground into a fine, fibrous pulp, which is then mixed with water. For dried roots, the material is finely ground, placed in a porous cloth, and infused in water. The resulting brew is usually consumed immediately after preparation, often from a communal bowl. Traditional and recreational preparation of kava beverage involves macerating, grinding, or pounding fresh or dried rhizome/root (1.0–1.5 g) and mixing it with water or coconut milk (100–150 mL) to form an emulsion, which is then agitated and strained through cloth or bark filters into a communal bowl. The resulting drink is grey and slightly pungent, with fresh rhizome/root producing a stronger and more complex beverage than dried forms due to the retention of volatile compounds. In Vanuatu, fresh root is commonly used, while in non-Pacific countries, kava is typically prepared from dried root powder soaked in water (about one tablespoon per cup) for 30 minutes before straining. On Pohnpei in Micronesia, preparation also includes mixing the kava root with the fibrous bark of Hibiscus tiliaceus before pressing.
Peukert argued that despite a turn towards Social Darwinism when confronted with the failure of the welfare state to solve all social problems in the 1920s, that it was the democratic Weimar constitution that had provided a thin legal wedge that prevented the full implications of this from being worked out. Peukert argued that in 1939 that the entire system that had been built up for scientifically identifying those of racial "non-value" served as the apparatus for genocide. Peukert wrote that all of the criteria for identifying Jews and Romany as peoples of racial "non-value" were based on the pseudo-scientific theories that had been promoted by generations of "race scientists" and that those serving in the "human sciences and social professions" worked to provide the theories for an "all-embracing racist restructuring of social policy, educational policy and health and welfare policy". The culmination of these efforts was the proposed 1944 "Law for the Treatment of Community Aliens" which called for sending to the concentration camps anyone who failed to live be up to be a proper 'volksgenossen as a gemeinschaftsfremde (community alien). Only the fact that Germany was fully engaged in World War II prevented Hitler from signing "Law for the Treatment of Community Aliens", which was put off until the Reich won the "final victory". Peukert wrote: "Nazi racism, the professed goal which had been to secure the immortality of the racially pure volkskörper in practice inevitably became converted into a crusade against life".
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.